Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Epigenetic deregulated miR-375 contributes to the constitutive activation of JAK2/STAT signaling in myeloproliferative neoplasm.

Leukemia research - 1 Apr 2015

Yin Li-hui, Zheng Xiao-qun, Li Hai-ying, Bi Lai-xi, Shi Yi-fen, Ye Ai-fang, Wu Jian-bo, Gao Shen-meng

Abstract excerpt

Constitutive activation of Janus kinase 2/signal transducers and activators of transcription (JAK2/STAT) signaling caused by JAK2V617F and other mutations is central to the pathogenesis of myeloproliferative neoplasm (MPN). Negative regulators such as suppressors of cytokine signaling (SOCS) inhibit activated JAK2/STAT signaling. However, whether silencing of negative regulators facilitates JAK2/STAT signaling is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chromatin Immunoprecipitation
Share to Epigenesis, Genetic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Janus Kinase 2

Share to MicroRNAs

Share to Myeloproliferative Disorders

Share to Real-Time Polymerase Chain Reaction

Share to STAT Transcription Factors

Share to Tumor Cells, Cultured

Source

Identifiers

PMID: 25666256
DOI: 10.1016/j.leukres.2015.01.009

Genes

JAK2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Epigenetic deregulated miR-375 contributes to the constitutive activation of JAK2/STAT signaling in myeloproliferative neoplasm.PMID 25666256Read ↗

[Inhibitors of JAK2/STAT Signaling Pathway and Hematologic Malignancies-Review].Semantic proximity Read ↗

JAK-STAT pathway in hematological malignancies: achievements, challenges and future perspectivesSemantic proximity Read ↗

Janus Kinase-Signal Transducer and Activator of Transcription Inhibitors for the Treatment and Management of CancerSemantic proximity Read ↗

Epigenetic silencing of SOCS 5 potentiates JAK ‐ STAT signaling and progression of T‐cell acute lymphoblastic leukemiaSemantic proximity Read ↗

HDAC8 overexpression in mesenchymal stromal cells from JAK2+ myeloproliferative neoplasms: a new therapeutic target?Semantic proximity Read ↗

Dnmt3a is downregulated by Stat5a and mediates G0/G1 arrest by suppressing the miR-17-5p/Cdkn1a axis in Jak2V617F cells.Semantic proximity Read ↗

STAT3 Inhibitors: Finding a Home in Lymphoma and LeukemiaSemantic proximity Read ↗

JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation.Semantic proximity Read ↗

HDAC11 deficiency disrupts oncogene-induced hematopoiesis in myeloproliferative neoplasms.Semantic proximity Read ↗

JAK/STAT signal transduction: regulators and implication in hematological malignancies.Semantic proximity Read ↗

SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activitySemantic proximity Read ↗

Regulation of SOX11 expression through CCND1 and STAT3 in mantle cell lymphomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.